Figure S1. Suppressed cell growth and increased sensitivity to MMC in FANCD2-depleted primary and transformed human cells. A) A Western blot comparing levels of endogenous FANCD2 with the expression of HA-FANCD2 transgene in complemented PD20 cells. B) A growth curve comparing survival of vector-only and transgene-expressing PD20 cells after treatment with the indicated doses of
2 MMC for 1hr. Two independent clones derived from PD20 and stably expressing wild type HA-FANCD2 were used. HA-FANCD2 K561R is a clone expressing a ubiquitination mutant of FANCD2. Cell growth was quantified as described in Supplemental Materials and Methods 4 days after treatment. C) A growth curve comparing survival of vector-only and FANCD2 shRNA-expressing GM639cc1 cells after treatment with the indicated doses of MMC for 1hr. Cell growth was quantified as above on day 5 after treatment. D, E) Isogenic primary human fibroblast (HFF4) and keratinocyte (HFK4) cells expressing non-specific shRNA (shNS) or FANCD2 shRNAs (FANCD2-40 or FANCD2-41) were plated at 50,000 (HFF4) or 100,000 (HFK4) cells per well in 6-well plates. Cell number was counted in duplicate samples every two days to determine population doubling levels (PDLs) according to a formula PDL=ln(cell number on day N/cell number on day N+1)/0.693. PDLs were averaged and plotted. Error bars are standard deviations. Note that in some cases error bars are too small to show over markers. 
